Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times ...
Impact of early-onset colorectal cancer on utilization of chemotherapy and outcomes in patients with stage II disease. This is an ASCO Meeting Abstract from the 2023 ASCO Gastrointestinal Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback